Raloxifene Teva

Land: Den Europæiske Union

Sprog: engelsk

Kilde: EMA (European Medicines Agency)

Køb det nu

Indlægsseddel Indlægsseddel (PIL)
27-09-2021
Produktets egenskaber Produktets egenskaber (SPC)
27-09-2021

Aktiv bestanddel:

raloxifene hydrochloride

Tilgængelig fra:

Teva B.V.

ATC-kode:

G03XC01

INN (International Name):

raloxifene

Terapeutisk gruppe:

Sex hormones and modulators of the genital system,

Terapeutisk område:

Osteoporosis, Postmenopausal

Terapeutiske indikationer:

Raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated.When determining the choice of raloxifene or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.

Produkt oversigt:

Revision: 10

Autorisation status:

Authorised

Autorisation dato:

2010-04-29

Indlægsseddel

                                20
B. PACKAGE LEAFLET
21
PACKAGE LEAFLET: INFORMATION FOR THE USER
RALOXIFENE TEVA 60 MG FILM-COATED TABLETS
raloxifene hydrochloride
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What Raloxifene Teva is and what it is used for
2.
What you need to know before you take Raloxifene Teva
3.
How to take Raloxifene Teva
4.
Possible side effects
5.
How to store Raloxifene Teva
6.
Contents of the pack and other information
1.
WHAT RALOXIFENE TEVA IS AND WHAT IT IS USED FOR
Raloxifene Teva is used to treat and prevent osteoporosis in
postmenopausal women. Raloxifene Teva
reduces the risk of vertebral fractures in women with postmenopausal
osteoporosis. A reduction in the
risk of hip fractures has not been shown.
How Raloxifene Teva works
Raloxifene Teva belongs to a group of non-hormonal medicines called
selective oestrogen receptor
modulators (SERMs). When a woman reaches the menopause, the level of
the female sex hormone
oestrogen goes down. Raloxifene Teva mimics some of the helpful
effects of oestrogen after the
menopause.
Osteoporosis is a disease that causes your bones to become thin and
fragile - this disease is especially
common in women after the menopause. Although it may have no symptoms
at first, osteoporosis
makes you more likely to break bones, especially in your spine, hips
and wrists and may cause back
pain, loss of height and a curved back.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE RALOXIFENE TEVA
DO NOT TAKE RALOXIFENE TEVA
-
If you are allergic to raloxifene or any of the other ingredien
                                
                                Læs hele dokumentet
                                
                            

Produktets egenskaber

                                1
_ _
_ _
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Raloxifene Teva 60 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 60 mg raloxifene hydrochloride,
equivalent to 56 mg raloxifene free
base.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
White to off-white, film coated, oval shaped tablets, embossed with
the number “60” on one side and
“N” on the other side of the tablet.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Raloxifene is indicated for the treatment and prevention of
osteoporosis in postmenopausal women. A
significant reduction in the incidence of vertebral, but not hip
fractures has been demonstrated.
When determining the choice of raloxifene or other therapies,
including oestrogens, for an individual
postmenopausal woman, consideration should be given to menopausal
symptoms, effects on uterine
and breast tissues, and cardiovascular risks and benefits (see section
5.1).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The recommended dose is one tablet daily.Due to the nature of this
disease process, raloxifene is
intended for long term use.
Generally calcium and vitamin D supplements are advised in women with
a low dietary intake.
_Elderly: _
No dose adjustment is necessary for the elderly.
_Patients with renal impairment: _
Raloxifene should not be used in patients with severe renal impairment
(see section 4.3). In patients
with moderate and mild renal impairment, raloxifene should be used
with caution.
_Patients with hepatic impairment_
:
Raloxifene should not be used in patients with hepatic impairment (see
section 4.3 and 4.4).
_Paediatric population: _
Raloxifene should not be used in children of any age. There is no
relevant use of Raloxifene in the
paediatric population.
Method of administration
Oral administration.
The tablet can be taken at any time of the day without regard to
meals.
3
4.3
CONTRAINDICATIONS
Hypersensitivity to the active subst
                                
                                Læs hele dokumentet
                                
                            

Dokumenter på andre sprog

Indlægsseddel Indlægsseddel bulgarsk 27-09-2021
Produktets egenskaber Produktets egenskaber bulgarsk 27-09-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport bulgarsk 06-05-2015
Indlægsseddel Indlægsseddel spansk 27-09-2021
Produktets egenskaber Produktets egenskaber spansk 27-09-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport spansk 06-05-2015
Indlægsseddel Indlægsseddel tjekkisk 27-09-2021
Produktets egenskaber Produktets egenskaber tjekkisk 27-09-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport tjekkisk 06-05-2015
Indlægsseddel Indlægsseddel dansk 27-09-2021
Produktets egenskaber Produktets egenskaber dansk 27-09-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport dansk 06-05-2015
Indlægsseddel Indlægsseddel tysk 27-09-2021
Produktets egenskaber Produktets egenskaber tysk 27-09-2021
Indlægsseddel Indlægsseddel estisk 27-09-2021
Produktets egenskaber Produktets egenskaber estisk 27-09-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport estisk 06-05-2015
Indlægsseddel Indlægsseddel græsk 27-09-2021
Produktets egenskaber Produktets egenskaber græsk 27-09-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport græsk 06-05-2015
Indlægsseddel Indlægsseddel fransk 27-09-2021
Produktets egenskaber Produktets egenskaber fransk 27-09-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport fransk 06-05-2015
Indlægsseddel Indlægsseddel italiensk 27-09-2021
Produktets egenskaber Produktets egenskaber italiensk 27-09-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport italiensk 06-05-2015
Indlægsseddel Indlægsseddel lettisk 27-09-2021
Produktets egenskaber Produktets egenskaber lettisk 27-09-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport lettisk 06-05-2015
Indlægsseddel Indlægsseddel litauisk 27-09-2021
Produktets egenskaber Produktets egenskaber litauisk 27-09-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport litauisk 06-05-2015
Indlægsseddel Indlægsseddel ungarsk 27-09-2021
Produktets egenskaber Produktets egenskaber ungarsk 27-09-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport ungarsk 06-05-2015
Indlægsseddel Indlægsseddel maltesisk 27-09-2021
Produktets egenskaber Produktets egenskaber maltesisk 27-09-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport maltesisk 06-05-2015
Indlægsseddel Indlægsseddel hollandsk 27-09-2021
Produktets egenskaber Produktets egenskaber hollandsk 27-09-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport hollandsk 06-05-2015
Indlægsseddel Indlægsseddel polsk 27-09-2021
Produktets egenskaber Produktets egenskaber polsk 27-09-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport polsk 06-05-2015
Indlægsseddel Indlægsseddel portugisisk 27-09-2021
Produktets egenskaber Produktets egenskaber portugisisk 27-09-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport portugisisk 06-05-2015
Indlægsseddel Indlægsseddel rumænsk 27-09-2021
Produktets egenskaber Produktets egenskaber rumænsk 27-09-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport rumænsk 06-05-2015
Indlægsseddel Indlægsseddel slovakisk 27-09-2021
Produktets egenskaber Produktets egenskaber slovakisk 27-09-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport slovakisk 06-05-2015
Indlægsseddel Indlægsseddel slovensk 27-09-2021
Produktets egenskaber Produktets egenskaber slovensk 27-09-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport slovensk 06-05-2015
Indlægsseddel Indlægsseddel finsk 27-09-2021
Produktets egenskaber Produktets egenskaber finsk 27-09-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport finsk 06-05-2015
Indlægsseddel Indlægsseddel svensk 27-09-2021
Produktets egenskaber Produktets egenskaber svensk 27-09-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport svensk 06-05-2015
Indlægsseddel Indlægsseddel norsk 27-09-2021
Produktets egenskaber Produktets egenskaber norsk 27-09-2021
Indlægsseddel Indlægsseddel islandsk 27-09-2021
Produktets egenskaber Produktets egenskaber islandsk 27-09-2021
Indlægsseddel Indlægsseddel kroatisk 27-09-2021
Produktets egenskaber Produktets egenskaber kroatisk 27-09-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport kroatisk 06-05-2015

Søg underretninger relateret til dette produkt